一种新的弥漫性大b细胞淋巴瘤预后预测模型的临床价值。

Q4 Medicine

中国实验血液学杂志 Pub Date : 2025-06-01 DOI:10.19746/j.cnki.issn.1009-2137.2025.03.024

Jie Zhao, Yan Jiang, Jia-Yu Liu, Rui Liu, Jia-Qi Li, Fang Huang, Jiang-Bo Wan, Si-Guo Hao

{"title":"一种新的弥漫性大b细胞淋巴瘤预后预测模型的临床价值。","authors":"Jie Zhao, Yan Jiang, Jia-Yu Liu, Rui Liu, Jia-Qi Li, Fang Huang, Jiang-Bo Wan, Si-Guo Hao","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.024","DOIUrl":null,"url":null,"abstract":"Objective: To explore a predictive model that can better predict the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), and validate its clinical value.Methods: Clinical data of 134 newly treated DLBCL patients were collected from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2015 to January 2020. Several risk factors of the patients were screened and analyzed, a novel prognostic model were then established based on this, and its clinical application potential was validated.Results: In the novel model, predicting progression-free survival (PFS) based on the age at initial treatment, albumin level, Hans classification, Ann Arbor stage, and BCL2 expression showed better predictive performance than International Prognostic Index (IPI) score (AUC: 0.788 vs 0.620，P <0.001). Predicting overall survival (OS) based on the age at initial treatment, albumin level, lactate dehydrogenase (LDH) level, and expressions of BCL2 and MUM1 proteins also showed better predictive performance for mortality risk than IPI score (AUC: 0.817 vs 0.624，P <0.001).Conclusion: This novel prognostic model can better predict the survival prognosis of DLBCL patients compared to the IPI scoring system.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"789-795"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Clinical Value of a Novel Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma].\",\"authors\":\"Jie Zhao, Yan Jiang, Jia-Yu Liu, Rui Liu, Jia-Qi Li, Fang Huang, Jiang-Bo Wan, Si-Guo Hao\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2025.03.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To explore a predictive model that can better predict the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), and validate its clinical value.Methods: Clinical data of 134 newly treated DLBCL patients were collected from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2015 to January 2020. Several risk factors of the patients were screened and analyzed, a novel prognostic model were then established based on this, and its clinical application potential was validated.Results: In the novel model, predicting progression-free survival (PFS) based on the age at initial treatment, albumin level, Hans classification, Ann Arbor stage, and BCL2 expression showed better predictive performance than International Prognostic Index (IPI) score (AUC: 0.788 vs 0.620，P <0.001). Predicting overall survival (OS) based on the age at initial treatment, albumin level, lactate dehydrogenase (LDH) level, and expressions of BCL2 and MUM1 proteins also showed better predictive performance for mortality risk than IPI score (AUC: 0.817 vs 0.624，P <0.001).Conclusion: This novel prognostic model can better predict the survival prognosis of DLBCL patients compared to the IPI scoring system.\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":\"33 3\",\"pages\":\"789-795\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的：探索一种能较好预测弥漫大b细胞淋巴瘤（DLBCL）患者预后的预测模型，并验证其临床价值。方法：收集2015年1月至2020年1月上海交通大学医学院附属新华医院新治的134例DLBCL患者的临床资料。筛选并分析患者的多个危险因素，在此基础上建立新的预后模型，并验证其临床应用潜力。结果：在新模型中，基于初始治疗年龄、白蛋白水平、Hans分类、Ann Arbor分期、BCL2表达预测无进展生存期（PFS）的预测效果优于国际预后指数（IPI）评分（AUC: 0.788 vs 0.620,P vs 0.624，P）。结论：该新模型与IPI评分系统相比，能更好地预测DLBCL患者的生存预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Clinical Value of a Novel Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma].

Objective: To explore a predictive model that can better predict the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), and validate its clinical value.

Methods: Clinical data of 134 newly treated DLBCL patients were collected from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2015 to January 2020. Several risk factors of the patients were screened and analyzed, a novel prognostic model were then established based on this, and its clinical application potential was validated.

Results: In the novel model, predicting progression-free survival (PFS) based on the age at initial treatment, albumin level, Hans classification, Ann Arbor stage, and BCL2 expression showed better predictive performance than International Prognostic Index (IPI) score (AUC: 0.788 vs 0.620，P <0.001). Predicting overall survival (OS) based on the age at initial treatment, albumin level, lactate dehydrogenase (LDH) level, and expressions of BCL2 and MUM1 proteins also showed better predictive performance for mortality risk than IPI score (AUC: 0.817 vs 0.624，P <0.001).

Conclusion: This novel prognostic model can better predict the survival prognosis of DLBCL patients compared to the IPI scoring system.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊